Pleasure of the aperitif for some or on the morning toast for others, peanuts represent a danger for those who are allergic to peanuts.
The results come from a phase 3 clinical trial carried out in eighteen European hospitals. Scientists were looking to evaluate a desensitization strategy by exposure to increasing doses of allergens.
In conclusion, the allergic reaction was considerably reduced in those who received oral immunotherapy treatment.
58% of people desensitized
The nine-month-long study involved the participation of 175 minors, aged 4 to 17, who were allergic to peanuts.
Three-quarters of them (132 exactly) took a new treatment based on AR101, a molecule derived from peanuts. The doses were increasing during the first six months to reach a plateau of 300 mg thereafter. Placebo was given to the remaining quarter of the participants.
The results of the study highlighted the good assimilation of the treatment. 58% of the young people who benefited from it had no allergic reaction when consuming peanuts, which was also the case for 2% of those subjected to the placebo.
However, the researchers specify that this desensitization treatment is not curative. It only helps to reduce the effects of allergy.